AI-Driven Target Discovery in LUSC: Validating a Multi-Omics Platform Through Rediscovery of Known and Novel Biology

Many cancers remain without effective treatments because their tumors lack identifiable or druggable driver mutations, exhibit resistance to immunotherapy, or acquire resistance to targeted precision therapy. Aignostics and Bayer have developed an AI-driven Target ID Platform that integrates multi-omics data and machine learning to identify complex biological patterns and reveal novel therapeutic hypotheses.

This case study demonstrates the Platform's validation in lung squamous cell carcinoma (LUSC), where it successfully identified distinct patient subgroups and recapitulated known cancer mechanisms while identifying unique molecular signatures that could lead to the generation of novel therapeutic hypotheses.